Company profile for Pluristyx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx provides seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD™) Pluripotent Stem Cells at a commercial scal...
Pluristyx was established in 2018 as an advanced therapy tools company to help companies and researchers solve manufacturing challenges in the field of drug development, regenerative medicine, and cell and gene therapy. Pluristyx provides seamless client support by offering CMC consulting, contract development services, and research- and clinical-grade Ready-To-Differentiate (RTD™) Pluripotent Stem Cells at a commercial scale and under GMP conditions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Pluristyx, Inc. 454 N 34th St Suite 200 Seattle, WA 98103
Telephone
Telephone
Client Website
Website
--
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/17/3189000/0/en/Pluristyx-Collaborates-with-Breakthrough-T1D-to-Make-Immune-Cloaked-and-Safety-Switch-Enabled-Allogeneic-Cell-Line-for-Type-1-Diabetes-Therapies.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181316/0/en/Pluristyx-Executes-Key-Commercial-Clinical-Use-Licenses-for-iPSC-Portfolio-Enabling-Novel-Therapies-for-Regenerative-Medicine-and-Neurological-Disease-Therapeutics.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/09/04/3144362/0/en/Pluristyx-and-BioLamina-Announce-Strategic-Partnership-to-Accelerate-Development-of-Stem-Cell-Based-Therapies.html

GLOBENEWSWIRE
04 Sep 2025

https://www.businesswire.com/news/home/20250728561286/en/Pluristyx-Completes-Investment-Round-to-Expand-Product-Portfolio-and-Commercial-Operations

BUSINESSWIRE
28 Jul 2025

https://www.businesswire.com/news/home/20250612648308/en/Pluristyx-Launches-PluriForm-Organoid-Kit-Slashing-Weeks-Off-Organoid-Development-Timelines

BUSINESSWIRE
12 Jun 2025

https://www.globenewswire.com/news-release/2025/03/19/3045322/0/en/Teknova-and-Pluristyx-Launch-Proprietary-PluriFreeze-Cryopreservation-System-to-Accelerate-the-Development-of-Cell-Therapies.html

GLOBENEWSWIRE
19 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty